

HCA Healthcare (HCA)

Target Pricing

Date: 6/25/2026
Ticker: HCA
Exchange: NYSE
Analyst: Kenneth Gannon

Currency: USD (\$mm)
Fiscal Year End: Late December

DISCLAIMER: This financial model is prepared for informational and educational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. All projections are estimates based on publicly available information and involve significant uncertainty.

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	Average
(\$mm)											
Revenue	41,490	43,614	46,677	51,336	51,533	58,752	60,233	64,968	70,603	75,600	
Gross Profit	34,557	36,298	38,953	42,855	43,164	22,492	23,177	25,579	28,678	31,374	
Gross Margin %	83.3%	83.2%	83.5%	83.5%	83.8%	38.3%	38.5%	39.4%	40.6%	41.5%	61.5%
SGA	18897	20059	21425	23560	23874	26779	27685	29487	31170	7997	
SGA % of Revenue	46%	46%	46%	46%	46%	46%	46%	45%	44%	11%	42.1%
Other Expenses	9462	10182	10886	12077	12028	-13965	-13561	-13535	-13039	11412	
OE % of Revenue	23%	23%	23%	24%	23%	-24%	-23%	-21%	-18%	15%	4.6%
EBIT	6,198	6,057	6,642	7,218	7,262	9,678	9,053	9,627	10,547	11,965	
EBIT Margin %	14.9%	13.9%	14.2%	14.1%	14.1%	16.5%	15.0%	14.8%	14.9%	15.8%	14.8%
EBITDA	8,483	8,202	9,368	9,664	9,735	14,252	13,290	12,721	13,896	15,603	
EBITDA Margin %	20.4%	18.8%	20.1%	18.8%	18.9%	24.3%	22.1%	19.6%	19.7%	20.6%	20.3%
D&A	2,285	2,145	2,726	2,446	2,473	4,574	4,237	3,094	3,349	3,638	
D&A % of Revenue	5.51%	4.92%	5.84%	4.76%	4.80%	7.79%	7.03%	4.76%	4.74%	4.81%	5.5%
Interest Expense	1598	1670	1765	1841	1560	1529	1739	1938	2061	2248	
CapEx	2,760	3,015	3,573	4,158	2,835	3,577	4,395	4,744	4,875	4,944	
CapEx % of Revenue	6.65%	6.91%	7.65%	8.10%	5.50%	6.09%	7.30%	7.30%	6.90%	6.54%	6.9%
Change in NWC	42	(296)	33	(88)	1,278	(503)	(1,152)	(457)	(106)	728	
NWC Change % of Revenue Change		-13.94%	1.08%	-1.89%	648.73%	-6.97%	-77.79%	-9.65%	-1.88%	14.57%	1.0%
Net Income	2,890	2,216	3,787	3,505	3,754	6,956	5,643	5,242	5,760	6,784	
EBT	4,810	4,381	5,335	5,244	5,430	9,833	8,580	7,706	8,523	9,832	
Effective Tax Rate	28.6%	37.4%	17.7%	21.0%	19.2%	21.5%	20.3%	21.0%	21.9%	20.9%	22.9%

PROJECTION ASSUMPTIONS (FY2027E–FY2036E)

Bear					
Year / Scenario	2026	2027	2028	2029	2030
Revenue Growth %	3.5%	3.4%	3.3%	3.1%	3.0%
Gross Margin %	40.0%	39.8%	39.5%	39.3%	39.0%
SGA % of Revenue	12.1%	11.8%	11.6%	11.3%	11.1%
OE % of Revenue	16.1%	15.8%	15.6%	15.3%	15.1%
DA % of Revenue	5.3%	5.1%	4.8%	4.6%	4.3%
CapEx % of Revenue	7.4%	7.1%	6.9%	6.6%	6.4%
NWC Chg % of Rev Chg	1.5%	1.3%	1.0%	0.8%	0.5%
Tax Rate	22.9%	22.9%	22.9%	22.9%	22.9%

Base					
Year / Scenario	2026	2027	2028	2029	2030
Revenue Growth %	4.0%	3.8%	3.5%	3.3%	3.0%
Gross Margin %	41.5%	41.3%	41.0%	40.8%	40.5%
SGA % of Revenue	11.1%	10.8%	10.6%	10.3%	10.1%
OE % of Revenue	15.1%	14.8%	14.6%	14.3%	14.1%
DA % of Revenue	4.8%	4.6%	4.3%	4.1%	3.8%
CapEx % of Revenue	6.9%	6.6%	6.4%	6.1%	5.9%
NWC Chg % of Rev Chg	1.0%	0.8%	0.5%	0.3%	0.0%
Tax Rate	20.9%	20.9%	20.9%	20.9%	20.9%

Bull					
Year / Scenario	2026	2027	2028	2029	2030
Revenue Growth %	4.5%	4.1%	3.8%	3.4%	3.0%
Gross Margin %	41.5%	41.4%	41.3%	41.1%	41.0%
SGA % of Revenue	10.6%	10.3%	10.1%	9.8%	9.6%
OE % of Revenue	14.6%	14.3%	14.1%	13.8%	13.6%
DA % of Revenue	4.3%	4.1%	3.8%	3.6%	3.3%
CapEx % of Revenue	6.4%	6.1%	5.9%	5.6%	5.4%
NWC Chg % of Rev Chg	1.0%	0.8%	0.5%	0.3%	0.0%
Tax Rate	20.9%	20.9%	20.9%	20.9%	20.9%

DCF ASSUMPTIONS

Parameter	Bear	Base	Bull
WACC	7.44%	7.44%	7.44%
Terminal Growth Rate (TGR)	3.0%	3.0%	3.0%
Shares Outstanding (mm)	230.7	230.7	230.7
Total Debt	45,452.0	45,452.0	45,452.0

WACC CALCULATION — HCA Healthcare (HCA)

1. EQUITY CAPITAL STRUCTURE

Current Price	\$389.62 "as of 7/27/2026"
Market Capitalization (\$mm)	89,889.2

1. DEBT CAPITAL STRUCTURE

Senior Notes — \$700M @ 5.000% due 2028 (\$mm)	700.0	5.00%
Senior Notes — \$300M @ ~5.15% (floating, estimated) due 2028 (\$mm)	300.0	5.15%
Senior Notes — \$750M @ 5.250% due 2030 (\$mm)	750.0	5.25%
Senior Notes — \$500M @ 4.300% due 2030 (\$mm)	500.0	4.30%
Senior Notes — \$750M @ 5.500% due 2032 (\$mm)	750.0	5.50%
Senior Notes — \$1,000M @ 4.600% due 2032 (\$mm)	1,000.0	4.60%
Senior Notes — \$1,500M @ 5.750% due 2035 (\$mm)	1,500.0	5.75%
Senior Notes — \$1,000M @ 4.900% due 2035 (\$mm)	1,000.0	4.90%
Senior Notes — \$1,250M @ 6.200% due 2055 (\$mm)	1,250.0	6.20%
Senior Notes — \$750M @ 5.700% due 2055 (\$mm)	750.0	5.70%
Other Senior Notes & Debentures — \$35,200M @ ~5.1% (blended) various maturities 2026–2064/2095 (\$mm)	34,764.0	5.10%
Other Senior Secured Debt — \$1,021M @ 4.60% various maturities (\$mm)	1,021.0	4.60%
Commercial Paper — \$2,207M @ 4.30% ~18-day avg. life (\$mm)	2,207.0	4.30%
Total Financial Debt (\$mm) [Senior Notes only]	46,492.0	
Cash & Cash Equivalents (\$mm)	1,040.0	
Net Financial Debt (\$mm)	45,452.0	
Total Capital (\$mm) [Equity + Financial Debt]	136,381.2	
Equity Weight (E / V)	65.9%	
Debt Weight (D / V)	34.1%	

2. COST OF EQUITY (CAPM)

Risk-Free Rate (Rf)	4.49%
Equity Risk Premium (ERP)	4.18%
Beta (5-year monthly, levered)	1.13
Unlevered Beta	0.74
Cost of Equity [Rf + β × ERP]	9.21%

3. COST OF DEBT (Senior Notes)

\$700M x 5.00% Contribution	0.08%
\$300M x ~5.15% (Floating) Contribution	0.03%
\$750M x 5.25% Contribution	0.08%
\$500M x 4.3% Contribution	0.05%
\$750M x 5.5% Contribution	0.09%
\$1000M x 4.6% Contribution	0.10%
\$1500M x 5.75% Contribution	0.19%
\$1000M x 4.9% Contribution	0.11%
\$1250M x 6.2% Contribution	0.17%
\$750M x 5.7% Contribution	0.09%
\$35200M x 5.1% (Blended) Contribution	3.81%
\$1021M x 4.6% Contribution	0.10%
\$2207M x 4.3% Contribution	0.20%
Pre-Tax Cost of Debt (weighted avg coupon)	5.10%
Effective Tax Rate	20.85%
After-Tax Cost of Debt [$K_d \times (1 - t)$]	4.03%

4. WACC

WACC = $(E/V) \times K_e + (D/V) \times K_d(1-t)$	7.44%
Adjustments (Mid Cap WACC Adjustment)	

5. SCENARIO INPUTS SUMMARY

	Bear	Base	Bull
WACC	7.44%	7.44%	7.44%
Net Financial Debt (\$mm)	45,452.0	45,452.0	45,452.0

INCOME STATEMENT (\$mm)								
Fiscal Year End (Late December)	FY2023	FY2024	FY2025	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Bear								
Revenue	64,968	70,603	75,600	78,246	80,887	83,516	86,125	88,709
Cost of Goods Sold	39,389	41,925	44,226	46,948	48,734	50,527	52,321	54,113
Gross Profit	25,579	28,678	31,374	31,298	32,153	32,989	33,804	34,597
Gross Margin %	39.4%	40.6%	41.5%	40.0%	39.8%	39.5%	39.3%	39.0%
SG&A	29,487	31,170	7,997	9,451	9,567	9,669	9,756	9,827
Other Expenses	(13,535)	(13,039)	11,412	12,594	12,817	13,024	13,216	13,391
EBIT (Operating Income)	9,627	10,547	11,965	9,254	9,768	10,295	10,832	11,378
EBIT Margin %	14.8%	14.9%	15.8%	11.8%	12.1%	12.3%	12.6%	12.8%
+ D&A	3,094	3,349	3,638	4,157	4,095	4,019	3,929	3,825
EBITDA	12,721	13,896	15,603	13,410	13,863	14,314	14,761	15,204
EBITDA Margin %	19.6%	19.7%	20.6%	17.1%	17.1%	17.1%	17.1%	17.1%
Interest Expense	1,938	2,061	2,248	2,248	2,248	2,248	2,248	2,248
Other Expenses	(17)	(37)	(115)	-115	-115	-115	-115	-115
EBT (Pre-Tax Income)	7,706	8,523	9,832	7,121	7,635	8,162	8,699	9,245
Income Tax Expense	2,464	2,763	3,048	1,627	1,745	1,865	1,988	2,113
Net Income	5,242	5,760	6,784	5,494	5,891	6,297	6,711	7,133
Net Margin %	8.1%	8.2%	9.0%	7.0%	7.3%	7.5%	7.8%	8.0%
Base								
Revenue	64,968	70,603	75,600	78,624	81,572	84,427	87,171	89,786
Cost of Goods Sold	39,389	41,925	44,226	45,995	47,924	49,812	51,649	53,423
Gross Profit	25,579	28,678	31,374	32,629	33,649	34,615	35,522	36,364
Gross Margin %	39.4%	40.6%	41.5%	41.5%	41.3%	41.0%	40.8%	40.5%
SG&A	29,487	31,170	7,997	8,710	8,833	8,931	9,003	9,049
Other Expenses	(13,535)	(13,039)	11,412	11,868	12,110	12,322	12,505	12,656
EBIT (Operating Income)	9,627	10,547	11,965	12,050	12,706	13,362	14,014	14,659
EBIT Margin %	14.8%	14.9%	15.8%	15.3%	15.6%	15.8%	16.1%	16.3%
+ D&A	3,094	3,349	3,638	3,784	3,721	3,641	3,541	3,423
EBITDA	12,721	13,896	15,603	15,834	16,428	17,003	17,555	18,082
EBITDA Margin %	19.6%	19.7%	20.6%	20.1%	20.1%	20.1%	20.1%	20.1%
Interest Expense	1,938	2,061	2,248	2,248	2,248	2,248	2,248	2,248
Other Expenses	(17)	(37)	(115)	-115	-115	-115	-115	-115
EBT (Pre-Tax Income)	7,706	8,523	9,832	9,917	10,573	11,229	11,881	12,526
Income Tax Expense	2,464	2,763	3,048	2,068	2,205	2,341	2,477	2,612
Net Income	5,242	5,760	6,784	7,850	8,369	8,888	9,404	9,914
Net Margin %	8.1%	8.2%	9.0%	10.0%	10.3%	10.5%	10.8%	11.0%
Bull								
Revenue	64,968	70,603	75,600	79,002	82,261	85,346	88,226	90,873
Cost of Goods Sold	39,389	41,925	44,226	46,216	48,225	50,141	51,943	53,615
Gross Profit	25,579	28,678	31,374	32,786	34,035	35,205	36,283	37,258
Gross Margin %	39.4%	40.6%	41.5%	41.5%	41.4%	41.3%	41.1%	41.0%
SG&A	29,487	31,170	7,997	8,357	8,496	8,601	8,671	8,704
Other Expenses	(13,535)	(13,039)	11,412	11,531	11,801	12,030	12,215	12,354
EBIT (Operating Income)	9,627	10,547	11,965	12,898	13,739	14,574	15,397	16,200
EBIT Margin %	14.8%	14.9%	15.8%	16.3%	16.7%	17.1%	17.5%	17.8%
+ D&A	3,094	3,349	3,638	3,407	3,342	3,254	3,143	3,010
EBITDA	12,721	13,896	15,603	16,305	17,081	17,828	18,540	19,210
EBITDA Margin %	19.6%	19.7%	20.6%	20.6%	20.8%	20.9%	21.0%	21.1%
Interest Expense	1,938	2,061	2,248	2,248	2,248	2,248	2,248	2,248
Other Expenses	(17)	(37)	(115)	(115)	(115)	(115)	(115)	(115)
EBT (Pre-Tax Income)	7,706	8,523	9,832	14,172	14,948	15,695	16,407	17,077
Income Tax Expense	2,464	2,763	3,048	2,955	3,117	3,272	3,421	3,560
Net Income	5,242	5,760	6,784	11,217	11,831	12,422	12,986	13,516
Net Margin %	8.1%	8.2%	9.0%	14.2%	14.4%	14.6%	14.7%	14.9%

UNLEVERED FREE CASH FLOW (UFCF) — \$mm						
Projection Period: FY2027E–FY2031E	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E	Terminal Value
Bear						
EBIT	9,254	9,768	10,295	10,832	11,378	
Less: Taxes on EBIT	1,627	1,745	1,865	1,988	2,113	
NOPAT (Tax-Effectuated EBIT)	7,627	8,024	8,430	8,844	9,266	
+ Depreciation & Amortization	4,157	4,095	4,019	3,929	3,825	
– Capital Expenditures	5,786	5,780	5,759	5,723	5,673	
– Change in Net Working Capital	40	33	27	20	13	
Unlevered Free Cash Flow (UFCF)	5,957	6,305	6,663	7,030	7,405	171,619
UFCF Margin %	7.6%	7.8%	8.0%	8.2%	8.3%	
Fiscal Year Expected	1	2	3	4	5	
Present Value of Cash Flow	5544.15	5462.03	5372.21	5275.14	5171.29	
Base						
EBIT	12,050	12,706	13,362	14,014	14,659	
Less: Taxes on EBIT	2,068	2,205	2,341	2,477	2,612	
NOPAT (Tax-Effectuated EBIT)	9,983	10,502	11,021	11,537	12,047	
+ Depreciation & Amortization	3,784	3,721	3,641	3,541	3,423	
– Capital Expenditures	5,421	5,421	5,399	5,357	5,293	
– Change in Net Working Capital	31	22	15	7	0	
Unlevered Free Cash Flow (UFCF)	8,314	8,780	9,248	9,714	10,177	235,867
UFCF Margin %	10.6%	10.8%	11.0%	11.1%	11.3%	
Fiscal Year Expected	1	2	3	4	5	
Present Value of Cash Flow	7738.23	7605.59	7455.50	7288.99	7107.21	
Bull						
EBIT	12,898	13,739	14,574	15,397	16,200	
Less: Taxes on EBIT	2,955	3,117	3,272	3,421	3,560	
NOPAT (Tax-Effectuated EBIT)	9,944	10,622	11,302	11,976	12,639	
+ Depreciation & Amortization	3,407	3,342	3,254	3,143	3,010	
– Capital Expenditures	5,052	5,055	5,031	4,981	4,903	
– Change in Net Working Capital	34	25	16	8	0	
Unlevered Free Cash Flow (UFCF)	8,263	8,884	9,508	10,131	10,746	249,056
UFCF Margin %	10.5%	10.8%	11.1%	11.5%	11.8%	
Fiscal Year Expected	1	2	3	4	5	
Present Value of Cash Flow	7690.90	7695.61	7665.71	7601.72	7504.64	

DCF VALUATION SUMMARY			
Parameter	Bear Case	Base Case	Bull Case
DISCOUNT FACTORS			
WACC	7.4%	7.4%	7.4%
Terminal Growth Rate (TGR)	3.0%	3.0%	3.0%
PRESENT VALUE OF UFCFs (\$mm)			
FY2026E	5,544	7,738	7,691
FY2027E	5,462	7,606	7,696
FY2028E	5,372	7,456	7,666
FY2029E	5,275	7,289	7,602
FY2030E	5,171	7,107	7,505
Terminal Value	171,619	235,867	249,056
PV of Terminal Value	119,854	164,723	173,934
% Terminal Value of Total EV	81.7%	81.6%	82.0%
ENTERPRISE VALUE & EQUITY VALUE (\$mm)			
Enterprise Value (EV)	146,679	201,918	212,092
Less: Net Debt / (+ Net Cash)	45,452	45,452	45,452
Equity Value	101,227	156,466	166,640
Diluted Shares Outstanding (mm)	230.7	230.7	230.7
Implied Share Price	\$438.76	\$678.19	\$722.29
Minimum	\$278	\$457	\$489
Maximum	\$585	\$879	\$934

TABLE 1: BASE CASE — Implied Share Price							
	2.25%	2.50%	2.75%	3.00%	3.25%	3.50%	3.75%
6.19%	\$879	\$739	\$730	\$721	\$712	\$704	\$695
6.44%	\$749	\$749	\$739	\$730	\$721	\$712	\$704
6.69%	\$758	\$749	\$739	\$730	\$721	\$712	\$704
6.94%	\$758	\$739	\$730	\$721	\$712	\$704	\$695
7.19%	\$749	\$721	\$712	\$704	\$695	\$687	\$678
7.44%	\$730	\$695	\$687	\$678	\$670	\$662	\$654
7.69%	\$704	\$662	\$654	\$646	\$638	\$630	\$623
7.94%	\$670	\$623	\$615	\$608	\$601	\$593	\$586
8.19%	\$630	\$579	\$572	\$566	\$559	\$552	\$546
8.44%	\$586	\$533	\$527	\$520	\$514	\$508	\$502
8.69%	\$539	\$485	\$479	\$474	\$468	\$463	\$457

TABLE 2: BULL CASE — Implied Share Price							
	2.25%	2.50%	2.75%	3.00%	3.25%	3.50%	3.75%
6.19%	\$934	\$787	\$777	\$768	\$758	\$749	\$740
6.44%	\$797	\$797	\$787	\$777	\$768	\$758	\$749
6.69%	\$806	\$797	\$787	\$777	\$768	\$758	\$749
6.94%	\$806	\$787	\$777	\$768	\$758	\$749	\$740
7.19%	\$797	\$768	\$758	\$749	\$740	\$731	\$722
7.44%	\$777	\$740	\$731	\$722	\$714	\$705	\$697
7.69%	\$749	\$705	\$697	\$688	\$680	\$672	\$664
7.94%	\$714	\$664	\$656	\$648	\$640	\$633	\$625
8.19%	\$672	\$618	\$611	\$603	\$596	\$589	\$582
8.44%	\$625	\$569	\$562	\$556	\$549	\$543	\$537
8.69%	\$576	\$518	\$512	\$506	\$501	\$495	\$489

TABLE 3: BEAR CASE — Implied Share Price							
	2.25%	2.50%	2.75%	3.00%	3.25%	3.50%	3.75%
6.19%	\$585	\$483	\$477	\$470	\$464	\$457	\$451
6.44%	\$490	\$490	\$483	\$477	\$470	\$464	\$457
6.69%	\$497	\$490	\$483	\$477	\$470	\$464	\$457
6.94%	\$497	\$483	\$477	\$470	\$464	\$457	\$451
7.19%	\$490	\$470	\$464	\$457	\$451	\$445	\$439
7.44%	\$477	\$451	\$445	\$439	\$433	\$427	\$421
7.69%	\$457	\$427	\$421	\$415	\$410	\$404	\$398
7.94%	\$433	\$398	\$393	\$388	\$382	\$377	\$372
8.19%	\$404	\$367	\$362	\$357	\$352	\$347	\$342
8.44%	\$372	\$333	\$329	\$324	\$320	\$315	\$311
8.69%	\$338	\$298	\$294	\$290	\$286	\$282	\$278

Multiples Valuation — HCA Healthcare (HCA)

HCA FY2026E BASE CASE INPUTS

Revenue (\$mm)	78,624.0
EBITDA (\$mm)	15,834.0
EBIT (\$mm)	12,050.5
Net Income (\$mm)	7,849.7
EPS	\$34.02
Diluted Shares (mm)	230.71
Net Financial Debt (\$mm)	45,452.0
Current Share Price	\$389.62

PEER COMPANY DATA

COMPANY		MARKET DATA (\$mm)							TRADING MULTIPLES				DKS IMPLIED PRICE			
Company	Ticker	Mkt Cap (\$mm)	EV (\$mm)	NTM Rev (\$mm)	NTM EBITDA (\$mm)	NTM EBIT (\$mm)	NTM Net Inc (\$mm)	NTM EPS	EV / Revenue	EV / EBITDA	EV / EBIT	P / E	via EV/Rev	via EV/EBITDA	via EV/EBIT	via P/E
Tenet Healthcare Corp.	THC	17,875.6	28,314.4	22,333.8	7,053.0	6,257.0	1,628.3	\$17.73	1.3x	4.0x	4.5x	11.0x	\$235.04	\$78.51	\$39.35	\$373.53
Universal Health Services Inc.	UHS	10,048.9	15,125.9	19,393.2	2,675.6	1,907.8	1,641.0	\$25.31	0.8x	5.7x	7.9x	6.1x	\$68.79	\$190.99	\$217.12	\$208.35
Community Health Systems	CHS	539.0	10,582.6	11,781.9	2,193.0	1,825.0	15.3	\$0.11	0.9x	4.8x	5.8x	35.3x	\$109.09	\$134.18	\$105.87	\$1,200.41
Encompass Health	EHC	10,887.6	13,542.4	6,943.9	1,511.5	1,124.3	657.5	\$6.54	2.0x	9.0x	12.0x	16.6x	\$467.62	\$417.90	\$432.11	\$563.45
DuVita Inc.	DVA	14,859.5	27,843.6	14,516.5	2,869.5	2,021.8	1,521.0	\$17.28	1.9x	9.7x	13.8x	9.8x	\$456.65	\$468.94	\$522.33	\$332.39
Mean									1.4x	6.6x	8.8x	15.7x	\$267.44	\$258.10	\$263.36	\$535.62
Median									1.3x	5.7x	7.9x	10.4x	\$235.04	\$190.99	\$217.12	\$373.53
High									2.0x	9.7x	13.8x	35.3x	\$467.62	\$468.94	\$522.33	\$1,200.41
Low									0.8x	4.0x	4.5x	6.1x	\$68.79	\$78.51	\$39.35	\$208.35

HCA VALUATION SUMMARY — PEER MEDIAN IMPLIED PRICE

	EV/Rev	EV/EBITDA	EV/EBIT	P/E
Peer Median Multiple	1.3x	5.7x	7.9x	10.4x
HCA Implied Share Price (vs. FY2026E)	\$235.04	\$190.99	\$217.12	\$352.96
Current Share Price	\$389.62	\$389.62	\$389.62	\$389.62
Implied Upside / (Downside)	-39.7%	-51.0%	-44.3%	-9.4%

PREMIUM / DISCOUNT RATIONALE

TABLE 1: EV / Revenue											
		1.01x	1.14x	1.27x	1.39x	1.52x		EV/REV	EV/EBITDA	EV/EBIT	P/E
Bear	78246.00	\$147	\$190	\$233	\$276	\$319	Minimum	\$146.97	\$65.88	\$57.41	\$197.62
	Base	78624.00	\$149	\$192	\$235	\$278	Maximum	\$323.94	\$282.44	\$334.91	\$605.26
Bull	79002.00	\$150	\$194	\$237	\$281	\$324					

		TABLE 2: EV / EBITDA				
		4.52x	5.09x	5.7x	6.22x	6.78x
Bear	13410.50	\$46	\$99	\$132	\$164	\$197
Base	15834.00	\$113	\$152	\$191	\$230	\$269
Bull	16305.14	\$123	\$163	\$203	\$242	\$282

		TABLE 3: EV / EBIT				
		6.34x	7.14x	7.93x	8.72x	9.51x
Bear	9253.94	\$57	\$69	\$121	\$153	\$185
Base	12050.48	\$134	\$176	\$217	\$259	\$300
Bull	12898.44	\$158	\$202	\$246	\$291	\$335

		TABLE 4: Price / Earnings				
		8.30x	9.34x	10.37x	11.41x	12.45x
Bear	23.81	\$198	\$222	\$247	\$272	\$298
Base	34.02	\$282	\$318	\$353	\$388	\$424
Bull	48.62	\$404	\$454	\$504	\$555	\$605

Investment Summary — HCA Healthcare (HCA)

HCA Current Price \$389.62

VALUATION SUMMARY										
Metric	DCF Bear Case	DCF Base Case	DCF Bull Case	EV / Revenue	EV / EBITDA	EV / EBIT	P / E	Margin of Safety	Target Price (DCF)	Multiples
Implied Share Price	\$418.66	\$650.56	\$693.12	\$235.04	\$190.99	\$217.12	\$352.96	10%	\$542.90	\$249.03
Range	\$278.14 - \$584.82	\$457.44 - \$878.92	\$489.19 - \$934.25	\$146.97 - \$323.94	\$65.88 - \$282.44	\$57.41 - \$334.91	\$197.62 - \$605.26		39.34%	
Upside / (Downside) vs Current Price	7.5%	67.0%	77.9%	(39.7%)	(51.0%)	(44.3%)	(9.4%)			
WACC	7.4%	7.4%	7.4%							
Terminal Growth Rate	3.0%	3.0%	3.0%							
Enterprise Value (\$mm)	146,679	201,918	212,092							

#REF!					
Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue (\$mm)	78,624	81,572	84,427	87,171	89,786
Revenue Growth %	4.0%	3.8%	3.5%	3.3%	3.0%
EBITDA (\$mm)	15,834	16,428	17,003	17,555	18,082
EBITDA Margin %	20.1%	20.1%	20.1%	20.1%	20.1%
UFCF (\$mm)	8,314	8,780	9,248	9,714	10,177

#REF!					
Assumption	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Growth %	4.0%	3.8%	3.5%	3.3%	3.0%
Gross Margin %	41.5%	41.3%	41.0%	40.8%	40.5%
SG&A % of Revenue	11.1%	10.8%	10.6%	10.3%	10.1%
D&A % of Revenue	4.8%	4.6%	4.3%	4.1%	3.8%
CapEx % of Revenue	6.9%	6.6%	6.4%	6.1%	5.9%
Tax Rate	20.9%	20.9%	20.9%	20.9%	20.9%
EBIT Margin %	15.3%	15.6%	15.8%	16.1%	16.3%